1. Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Issue 5 (18th January 2018) Authors: Tan, Eng‐Huat; Lim, Wan‐Teck; Ahn, Myung‐Ju; Ng, Quan‐Sing; Ahn, Jin Seok; Shao‐Weng Tan, Daniel; Sun, Jong‐Mu; Han, May; Payumo, Francis C.; McKee, Krista; Yin, Wei; Credi, Marc; Agarwal, Shefali; Jac, Jaroslaw; Park, Keunchil Journal: Clinical pharmacology in drug development Issue: Volume 7:Issue 5(2018) Page Start: 532 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗